M5xhskpn6vgsof8wj0%3d&expires=1696150916

Team Megan Bugg

Megan Bugg / Honor Pages

I was diagnosed with stage 4 Alveolar Rhabdomyosarcoma (ARMS) on December 30, 2014. Since my original diagnosis and four relapses, I have been through 114 weeks of intense chemotherapy, over 120 radiation treatments, three surgeries, and too many short and long term side effects to mention. My mission is to raise awareness and funds for an exciting new drug called Entinostat that could be used to treat ARMS.  It is so important that this drug makes it to clinical trial.  I believe this drug could be the key to helping make sure that no more kids have to go through what I have experience at the hands of this awful disease.

  • $215,152

    Raised

  • $180,000

    Goal

  • 673

    Supporters

Recent Transactions

About Team Megan Bugg

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, adolescent and young adults. Clinically, survival amongst metastatic RMS patients has remained unacceptably low and unimproved for years, if not several decades. The most aggressive type of RMS is Alveolar Rhabdomyosarcoma (ARMS) has received very little clinical research and deserves more attention. It is unacceptable that no new agents have emerged for testing in clinical trials for high-risk or relapsed RMS in the last 6 years. As a result, the disease-free survival for ARMS have remained unchanged for 47 years!!! It is disheartening to know that NO primary drug approvals for RMS have occurred in history EVER...and only 8 drugs developed for any childhood cancer have been FDA approved since 1978. By comparison, 12 or more adult cancer drugs on average are FDA approved annually. CC-TDI is bringing new and exciting innovations and recent discoveries to the specific challenges posed by RMS, and I am excited to support one of their most promising research projects. My goal is to raise $180,000 for preclinical testing of a drug called Entinostat. This drug has shown tremendous promise in the CTDI labs as a potential treatment that could restore chemotherapy sensitivity and thereby improve outcomes for RMS patients. By raising $180,000, it will pay for the preclinical testing of Entinostat which will increase the likelihood that a full clinical trial will be approved. Kids like me who have been fighting RMS need hope, and getting this clinical trial funded will be the first glimmer of hope these kids and their families have ever received. Please help me support all of the brave kids who are fighting this terrible and devastating disease.

Facebook Comments